Loading stock…

Nutex Health Inc. (NUTX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Nutex Health Inc.

NUTXMarket cap $1.46BPrice $213.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Runs micro-hospitals and emergency rooms across the US, treating patients regardless of insurance status. Nutex bets on a model where ER visits alone can turn a facility profitable, flipping traditional hospital economics on its head.

In Bastion Portfolios?

52W Return+125%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+59%10

Revenue Forecast

Rev CAGR (1y)-1%2

Rev CAGR (3y)+5%4

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1-61%1

EPS Growth Y+2+4%5

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin57%10

Net Income Margin21%8

Free Cash Flow Margin32%9

Debt

Net Debt/EBITDA0.37

Efficiency

ROE57%10

ROA30%10

Earnings Stability33

GEAR+STRONG70

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)710

P/E Ratio (Forward 3y)431

P/BV3.74

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd510

Yield

Free Cash Flow Yield18.6%10

Dividend Yieldna–

Momentum

Short term

1 month return+12%10

3 month return+19%9

YTD return+29%8

Mid term

Price vs 52wHigh94%9

1 year return+107%10

Long term

3 year return+651%10

5 year return-96%1

Risk Shield

Price Risk

Beta2.11

Volatility91%1

Free Cash Flow

Free Cash Flow Margin32%9

Free Cash Flow Yield18.6%10

Quality

ROCE64%10

Earnings Stability33

Net Debt/EBITDA0.37

02Growth

Is it actually growing, and how fast?

NUTXNutex Health

Revenue FY25$875M

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+59%10

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-61%1

EPS growth, FY27E+4%5

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 59%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 59%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow in step with sales (EPS about 4%/yr vs revenue 5%/yr). One year dips: EPS falls 61% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG90 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+12%10

3-month return+19%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+107%10

3-year return+651%10

5-year return-96%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 107% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+12%), over three months (+19%) and so far this year (+29%).

WATCH

Average long-term results. Multi-year returns are middling (+651% over three years and -96% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Nutex Health Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NUTXNutex Health

Revenue FY25$875M

GROWTH RATING↗

AVERAGE42 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+59%10

Revenue, next 1Y-1%2

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-61%1

EPS growth, FY27E+4%5

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 59%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

A mid-pack grower, ahead of 42% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 59%/yr over the last 3 years; forecasts see it cooling to 5%/yr.

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow in step with sales (EPS about 4%/yr vs revenue 5%/yr). One year dips: EPS falls 61% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG90 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+12%10

3-month return+19%9

YTD return+29%8

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+107%10

3-year return+651%10

5-year return-96%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 107% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+12%), over three months (+19%) and so far this year (+29%).

WATCH

Average long-term results. Multi-year returns are middling (+651% over three years and -96% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Nutex Health Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community